Tweet
Profile
Adolor Corporation
700 Pennsylvania Drive
Exton, PA 19341
United States - Map
Phone: 484-595-1500
Fax: 484-595-1515
Website: http://www.adolor.com
Details
Index Membership: N/A
Sector: Healthcare
Industry: Drug Manufacturers - Other
Full Time Employees: 75
Business Summary
Adolor Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel prescription pain and pain management products. The company offers ENTEREG (alvimopan), a small molecule peripherally-acting mu-opioid receptor antagonist designed to block the adverse side effects of opioid analgesics on the gastrointestinal (GI) tract, as well as to accelerate upper and lower GI recovery following partial bowel resection surgery with primary anastomosis. It also has various product candidates in clinical development comprising peripherally-acting mu opioid receptor antagonists ADL5945, which is in phase II clinical trial to treat opioid-induced constipation; and ADL7445, a second peripherally-acting mu opioid receptor antagonist, which is considered a back-up compound. In addition, the company develops ADL6906 (beloxepin), a compound for treating chronic pain. Its preclinical products include centrally-acting mu opioid receptor antagonists for the treatment of l-DOPA-induced dyskinesia associated with the management of Parkinson’s disease. The company sells its products primarily to wholesale drug distributors. Adolor Corporation was founded in 1993 and is headquartered in Exton, Pennsylvania.
Adolor Corporation
700 Pennsylvania Drive
Exton, PA 19341
United States - Map
Phone: 484-595-1500
Fax: 484-595-1515
Website: http://www.adolor.com
Details
Index Membership: N/A
Sector: Healthcare
Industry: Drug Manufacturers - Other
Full Time Employees: 75
Business Summary
Adolor Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel prescription pain and pain management products. The company offers ENTEREG (alvimopan), a small molecule peripherally-acting mu-opioid receptor antagonist designed to block the adverse side effects of opioid analgesics on the gastrointestinal (GI) tract, as well as to accelerate upper and lower GI recovery following partial bowel resection surgery with primary anastomosis. It also has various product candidates in clinical development comprising peripherally-acting mu opioid receptor antagonists ADL5945, which is in phase II clinical trial to treat opioid-induced constipation; and ADL7445, a second peripherally-acting mu opioid receptor antagonist, which is considered a back-up compound. In addition, the company develops ADL6906 (beloxepin), a compound for treating chronic pain. Its preclinical products include centrally-acting mu opioid receptor antagonists for the treatment of l-DOPA-induced dyskinesia associated with the management of Parkinson’s disease. The company sells its products primarily to wholesale drug distributors. Adolor Corporation was founded in 1993 and is headquartered in Exton, Pennsylvania.